Skip to main content
SpringerLink
Log in

Clinical and therapeutic use of probucol

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Previous studies showed that probucol significantly lowered both LDL cholesterol and HDL cholesterol. In addition, there is evidence that as an essential anti-oxidant probucol causes variations in cellular interactions and cardiovascular functions in patients. Therefore, 14 hypercholesterolemic men were investigated before and during probucol treatment in order to document both serological and cardiovascular changes with special regard to (1) serum apolipoproteins (A-1, A-II, B, C-II, C-III, E) (2) composition and distribution of HDL and LDL subfractions, (3) cardiovascular performance using a maximum exercise stress test, and (4) induced platelet aggregation. In contrast to reduced total, LDL-, and HDL-cholesterol values, highly significant changes in serum apolipoproteins were found in apo A-I only; apoA-II was unchanged both in serum and in HDL subfractions. Despite unchanged serum apoB levels, the results showed that probucol has a significant influence on the composition (TG/FC ratio) of LDL particles of d < 1.019 g/ml. In addition to lipoprotein-related changes, significant decreases in heart rate data and cardiac work and in lactic acid accumulation during exercise were induced by probucol administration; furthermore, adrenaline-induced platelet aggregation was also decreased. The results found significantly demonstrate that probucol acts by way of more mechanisms than cholesterol lowering alone. This aspect may be of special interest in the clinical use of probucol, because a coronary-risk-reducing therapy should not affect the lipoprotein profile only.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ross R (1986) The pathogenesis of atherosclerosis — an update. N Engl J Med 314: 488–500

    PubMed  Google Scholar 

  2. Buckley M, Goa K, Price A, Brogden R (1989) Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 37: 761–800

    PubMed  Google Scholar 

  3. Miettinen TA, Huttunen JK, Naukkarinen, Strandberg T, Vanhanen H (1986) Long-term use of probucol in the multifactorial primary prevention of vascular disease. Am J Cardiol 57: 49H-54H

    PubMed  Google Scholar 

  4. Schwartz CJ (1988) The probucol experience: a review of the past and a look at the future. Am J Cardiol 62: 1B-5B

    Google Scholar 

  5. Berg A, Frey I, Baumstark M, Keul J (1988) Influence of probucol administration on serum lipoprotein cholesterol and apolipoproteins. Atherosclerosis 72: 49–54

    PubMed  Google Scholar 

  6. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J (1990) Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochim Biophys Acta 1037: 48–57

    PubMed  Google Scholar 

  7. Breddin K, Grun H, Krywanek HJ, Schremmer WP (1975) Zur Messung der spontanen Thrombozytenaggregation. Plättchenaggregationstest: III. Methodik. Klin Wochenschr 53: 81–89

    PubMed  Google Scholar 

  8. Lehmann M, Hasler K, Hasenfuß G, Holubarsch C, Staiger A, Kasper W, Keul J (1985) Zur induzierten Plättchenaggregation bei Patienten mit koronarer Herzkrankheit sowie trainierten und untrainierten Kontrollpersonen. Z Kardiol 74: 611–617

    PubMed  Google Scholar 

  9. Berg A, Keul J (1981) Physiological and metabolic responses of female athletes during laboratory and field exercise. Med Sport 14: 77–96

    Google Scholar 

  10. Cheung MC, Albers JJ (1984) Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but not A-II. J Biol Chem 259: 12201–12209

    PubMed  Google Scholar 

  11. Glass C, Pittman RC, Weinstein DB, Steinberg D (1985) Uptake of high-density lipoprotein-associated apolipoprotein A-I and cholesterolesters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J Biol Chem 260: 744–750

    PubMed  Google Scholar 

  12. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC Jr, Innerarity TL, Blackhart B, Taylor WH, Marcel Y, Milne R, Johnson D, Fuller M, Losis AJ, McCarthy BJ, Mahley RW, Levy-Wilson B, Scott J (1986) Complete protein sequence and identification of structurnal domains of human apolipoprotein B. Nature 323: 734–738

    PubMed  Google Scholar 

  13. Yang CY, Chen SH, Gianturco SH, Bradley WA, Sparrow JT, Tanimura M, Li WH, Sparrow DA, DeLoof H, Rosseneu M, Lee FS, Gu ZW, Gotto AM Jr, Chan L (1986) Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature 323: 738–742

    PubMed  Google Scholar 

  14. Beaumont JL, Jacotot B, Buxtorf JC, Silvestre M, Beaumont V (1982) Effects of probucol on the cholesterol content of skin in type II hyperlipidemias. Artery 10: 71–87

    PubMed  Google Scholar 

  15. Clemens MR, Waller HD (1987) Lipid peroxidation in erythrocytes. Chem Phys Lipids 45: 251–268

    PubMed  Google Scholar 

  16. Kamada T, Yamashita T, Baba Y, Kai Y, Setoyama S, Chuman Y, Otsuji S (1986) Dietary sardine oil increases erythrocyte membrane fluidity indiabetic patients. Diabetes 35: 604–611

    PubMed  Google Scholar 

  17. Niki E (1987) Antioxidants in relation to lipid peroxidation. Chem Phys Lipids 44: 227–253

    PubMed  Google Scholar 

  18. Richter C (1987) Biophysical consequences of lipid peroxidation in membranes. Chem Phys Lipids 44: 175–189

    PubMed  Google Scholar 

  19. Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV (1981) Enhanced in vivo platelet release reaction and melondialdehyde formation in patients with hyperlipidemia. Am J Med 70: 59–64

    PubMed  Google Scholar 

  20. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B (1986) Effects of probucol on xanthoma regression in familial hypercholesterolemia. Am J Cardiol 57: 29H-35H

    PubMed  Google Scholar 

  21. Shattil SJ, Anaya-Galindo R, Bennet J, Colman RW, Cooper RA (1975) Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55: 636–643

    PubMed  Google Scholar 

  22. Simons LA, Balasubramaniam S, Beins DM (1981) Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis 40: 299–308

    PubMed  Google Scholar 

  23. Sinha AK, Shattil SJ, Colman RW (1977) Cyclic AMP metabolism in cholesterol rich platelets. J Biol Chem 252: 3310–3314

    PubMed  Google Scholar 

  24. Stuart MJ, Gerrard JM, White JC (1980) Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 302: 6–10

    PubMed  Google Scholar 

  25. Alexandre A, Doni MG, Padoin E, Deana R (1986) Inhibition by antioxidants of agonist evoked cytosolic Ca + + increase, ATP secretion and aggregation of aspirinated human platelets. Biochem Biophys Res Commun 139: 509–514

    PubMed  Google Scholar 

  26. Muranov KD, Gashev SB, Smirnov LD, Shvedova AA, Ritov VB (1986) Ingibirovanie agregatsii trombotsitov antioksidantami. Biull Eksp Biol 101: 337–339

    Google Scholar 

  27. Salonen JT, Salonen R, Penttilä I, Herranen J, Jauhiainen M, Kantola M, Lappeteläinen R, Mäenpää P, Alfthan G, Puska P (1985) Serum fatty acids, apoproteins, selenium, and vitamin anti-oxidants and the risk of death from coronary artery disease. Am J Cardiol 56: 226–231

    PubMed  Google Scholar 

  28. Marshall PJ, Kulmacz RJ, Lands WEM (1987) Constraints on prostaglandin biosynthesis in tissues. J Biol Chem 262: 3510–3517

    PubMed  Google Scholar 

  29. Moncada S, Gryglewsky RJ, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665

    PubMed  Google Scholar 

  30. Ursini F, Bindoli A (1987) The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem Phys Lipids 44: 255–276

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Sport- und Leistungsmedizin, Klinikum der Albert-Ludwigs-Universität Freiburg, Medizinische Universitätsklinik und Poliklinik, Hugstetter Straße 55, W-7800, Freiburg, Germany

    A. Berg, M. W. Baumstark, I. Frey, M. Halle & J. Keul

Authors
  1. A. Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. W. Baumstark
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Halle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Keul
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, A., Baumstark, M.W., Frey, I. et al. Clinical and therapeutic use of probucol. Eur J Clin Pharmacol 40, S81–S84 (1991). https://doi.org/10.1007/BF01409415

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01409415

Key words

Search

Navigation